2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): what is new?

Cover Page

Cite item

Full Text

Abstract

The article presents key approaches to the diagnosis and treatment of atrial fibrillation in light of the new 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery. The main changes made to the new recommendations are reflected. The innovative patient-oriented principle of atrial fibrillation treatment — AF-CARE is considered in detail. An analysis of the updated scale for assessing the risk of stroke and systemic embolism CHA2DS2-VA is given. The article provides definitions of clinical, subclinical, trigger-induced, newly diagnosed, paroxysmal, persistent and permanent forms of atrial fibrillation, algorithms for the treatment of different forms of atrial fibrillation based on the choice of drug therapy taking into account the left ventricular ejection fraction. Much attention is paid to screening and early detection of atrial fibrillation. The categories of patients for whom screening is advisable are determined. The importance of early diagnostics of atrial cardiomyopathy using atrial myocardial strain analysis is emphasized. The role of timely, guideline-based treatment of comorbid pathology such as chronic heart failure, diabetes mellitus, obesity, obstructive sleep apnea, arterial hypertension and others is emphasized in order to prevent atrial fibrillation and, if it occurs, to reduce relapses.

About the authors

Tatiana N. Novikova

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: novikova-tn@mail.ru
ORCID iD: 0000-0003-4655-0297
SPIN-code: 3401-0329

MD, Cand. Sci. (Medicine)

Russian Federation, Saint Petersburg

Danila A. Kunshin

North-Western State Medical University named after I.I. Mechnikov

Email: rabotadanilakunshin@gmail.com
ORCID iD: 0009-0003-6314-4167
SPIN-code: 6104-1887

6th year student

Russian Federation, Saint Petersburg

Irina A. Dolinina

North-Western State Medical University named after I.I. Mechnikov

Email: dolinina-ira@mail.ru
ORCID iD: 0009-0005-9370-8554

5th year student

Russian Federation, Saint Petersburg

Lyubov S. Dyatchina

North-Western State Medical University named after I.I. Mechnikov

Email: lyubov.dyatchina@mail.ru
ORCID iD: 0009-0000-7558-4555

5th year student

Russian Federation, Saint Petersburg

Fatima I. Bitakova

North-Western State Medical University named after I.I. Mechnikov

Email: Fatima.Bitakova@szgmu.ru
ORCID iD: 0000-0001-6637-8266
SPIN-code: 8624-7193

MD, Cand. Sci. (Medicine)

Russian Federation, Saint Petersburg

Vladimir I. Novikov

North-Western State Medical University named after I.I. Mechnikov

Email: novikov-vi@mail.ru
ORCID iD: 0000-0002-2493-6300
SPIN-code: 6909-3377

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg

Sergey A. Sayganov

North-Western State Medical University named after I.I. Mechnikov

Email: sergey.saiganov@szgmu.ru
ORCID iD: 0000-0001-8325-1937
SPIN-code: 2174-6400
Scopus Author ID: 36140532200

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Saint Petersburg

References

  1. Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314–3414. doi: 10.1093/eurheartj/ehae176 EDN: TPYMAL
  2. Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russian Journal of Cardiology. 2021;26(7):190–260. doi: 10.15829/1560-4071-2021-4594 EDN: FUZAAD
  3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio- thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the european society of cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–349. doi: 10.1093/eurheartj/ehaa612 EDN: SSKKDD
  4. Belenkov YuN, Shakaryants GA, Khabarova NV, An GV. Anticoagulant therapy in elderly patients with atrial fibrillation. Kardiologiia. 2018;58(10):45–52. doi: 10.18087/cardio.2018.10.10177 EDN: YLGHJB
  5. Novikova ТN. The risk of bleeding minimization with direct oral anticoagulants. Atherothrombosis. 2021;(1):106–126. doi: 10.21518/2307-1109-2021-11-1-106-126 EDN: AOSWXN
  6. De with RR, Rienstra M, Nguyen BO, et al. Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace. 2020;22:1162–72. doi: 10.1093/europace/euaa123 EDN: EPRZDH
  7. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1261–74. doi: org/10.1001/jama.2019.0693
  8. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378(5):417–27. doi: 10.1056/NEJMoa1707855 EDN: XXDBJJ
  9. Svendsen JH, Diederichsen SZ, Højberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet. 2021;398(10310): 1507–1516. doi: 10.1016/s0140-6736(21)01698-6 EDN: PNEUVA
  10. Svennberg E, Friberg L, Frykman V, et al. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet. 2021;398(10310):1498–506. doi: 10.1016/S0140-6736(21)01637-8 EDN: YGLWVI
  11. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med. 2012;366(2):120–129. doi: 10.1056/NEJMoa1105575
  12. Lubitz SA, Yin X, Rienstra M, et al. Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2015;131(19):1648–1655. doi: 10.1161/CIRCULATIONAHA.114.014058 EDN: YCPEYC
  13. Wang EY, Hulme OL, Khurshid S, et al. Initial precipitants and recurrence of atrial fibrillation. Circ Arrhythm Electrophysiol. 2020;13(3):e007716. doi: 10.1161/CIRCEP.119.007716 EDN: ZJUMOR
  14. Corica B, Romiti GF, Basili S, Proietti M. Prevalence of new-onset atrial fibrillation and associated outcomes in patients with sepsis: a systematic review and meta-analysis. J Pers Med. 2022;12(4):547. doi: 10.3390/jpm12040547 EDN: XDNZQR
  15. Bedford JP, Ferrando-Vivas P, Redfern O, et al. New-onset atrial fibrillation in intensive care: epidemiology and outcomes. Eur Heart J Acute Cardiovasc Care. 2022;11(8):620–628. doi: 10.1093/ehjacc/zuac080 EDN: PLMSJN
  16. Coats AJS, Heymans S, Farmakis D, et al. Atrial disease and heart failure: the common soil hypothesis proposed by the heart failure association of the European Society of Cardiology. Eur Heart J. 2022:43(9):863–867. doi: 10.1093/eurheartj/ehab834 EDN: ZSWEFQ
  17. Schnabel RB, Marinelli EA, Arbelo E, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace. 2023;25(1):6–27. doi: 10.1093/europace/euac062 EDN: JFQFMB
  18. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/ APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10): 1455–1490. doi: 10.1093/europace/euw161 EDN: XUQHUD
  19. Pathan F, D'Elia N, Nolan MT, et al. Normal ranges of left atrial strain by speckle-tracking echocardiography: a systematic review and meta-analysis. J Am Soc Echocardiogr. 2017;30(1):59–70.e8. doi: 10.1016/j.echo.2016.09.007 EDN: XZTNYZ
  20. Novikova TN, Andreeva AE, Bitakova FI, et al. Multifaces of hypertrophic cardiomyopathy: a case of transformation of hypertrophic phenotype into dilated. Cardiac Arrhythmias. 2024;4(1):31–41. doi: 10.17816/cardar630134 EDN: MDUOTK
  21. Tomasdottir M, Friberg L, Hijazi Z, et al. Risk of ischemic stroke and utility of CHA2 DS2 –VASc score in women and men with atrial fibrillation. Clin Cardiol. 2019;42(10):1003–9. doi: 10.1002/clc.23257 EDN: BKBIBI
  22. Wu VC, Wu M, Aboyans V, et al. Female sex as a risk factor for ischaemic stroke varies with age in patients with atrial fibrillation. Heart. 2020;106(7):534–540. doi: 10.1136/heartjnl-2019-315065 EDN: THDVZU
  23. Mikkelsen AP, Lindhardsen J, Lip GY, et al. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost. 2012;10(9):1745–1751. doi: 10.1111/j.1538-7836.2012.04853.x EDN: WUSZOX
  24. Antonenko K, Paciaroni M, Agnelli G, et al. Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: results from the RAF study (early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation). Eur Stroke J. 2017;2(1):46–53. doi: 10.1177/2396987316679577 EDN: VJGUBH
  25. Chung S, Kim TH, Uhm JS, et al. Stroke and systemic embolism and other adverse outcomes of heart failure with preserved and reduced ejection fraction in patients with atrial fibrillation (from the COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation [CODE-AF]). Am J Cardiol. 2020;125(1):68–75. doi: 10.1016/j.amjcard.2019.09.035 EDN: QRXFNN
  26. Uhm JS, Kim J, Yu HT, et al. Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type. ESC Heart Fail. 2021;8(2):1582–9. doi: 10.1002/ehf2.13264 EDN: MFEEUA
  27. McMurray JJ, Ezekowitz JA, Lewis BS, et al. Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. Circ Heart Fail. 2013;6(3):451–60. doi: 10.1161/CIRCHEARTFAILURE.112.000143 EDN: RIMJIZ
  28. McEvoy JW, Touyz RM, McCarthy CP, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018. doi: 10.1093/eurheartj/ehae178
  29. Kim D, Yang PS, Kim TH, et al. Ideal blood pressure in patients with atrial fibrillation. J Am Coll Cardiol. 2018;72(11): 1233–1245. doi: 10.1016/j.jacc.2018.05.076
  30. Lip GY, Clementy N, Pericart L, et al. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire valley atrial fibrillation project. Stroke. 2015;46(1):143–150. doi: 10.1161/STROKEAHA.114.007199 EDN: YMYQJF
  31. American Diabetes Association (ADA). Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(S1):S17–S38. doi: 10.2337/dc22-s002 EDN: VUUZUZ
  32. Steensig K, Olesen KKW, Thim T, et al. Should the presence or extent of coronary artery disease be quantified in the CHA2DS2-VASc score in atrial fibrillation? A report from the western Denmark heart registry. Thromb Haemost. 2018;118(12):2162–2170. doi: 10.1055/s-0038-1675401 EDN: WYUPXD
  33. Zabalgoitia M, Halperin JL, Pearce LA, et al. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in atrial fibrillation III investigators. J Am Coll Cardiol. 1998;31(7):1622–1626. doi: 10.1016/S0735–1097(98)00146-6 EDN: AAVLEX
  34. Transesophageal echocardiography in atrial fibrillation: standards for acquisition and interpretation and assessment of interobserver variability. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. J Am Soc Echocardiogr. 1996;9(4):556–566.
  35. Lozier MR, Sanchez AM, Lee JJ, et al. Thromboembolic outcomes of different anticoagulation strategies for patients with atrial fibrillation in the setting of hypertrophic cardiomyopathy: a systematic review. J Atr Fibrillation. 2019;12(4):2207. doi: 10.4022/jafib.2207
  36. Guttmann OP, Rahman MS, O'Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014;100(6):465–472. doi: 10.1136/heartjnl-2013-304276
  37. Guttmann OP, Pavlou M, O'Mahony C, et al. Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA). Eur J Heart Fail. 2015;17(8):837–845. doi: 10.1002/ejhf.316 EDN: PTBPNY
  38. Vilches S, Fontana M, Gonzalez-Lopez E, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(8):1387–96. doi: 10.1002/ejhf.2566 EDN: GMQSXF
  39. Lee SE, Park JK, Uhm JS, et al. Impact of atrial fibrillation on the clinical course of apical hypertrophic cardiomyopathy. Heart. 2017;103(19):1496–1501. doi: 10.1136/heartjnl-2016-310720
  40. Hirota T, Kubo T, Baba Y, et al. Clinical profile of thromboembolic events in patients with hypertrophic cardiomyopathy in a regional Japanese cohort-results from Kochi RYOMA study. Circ J. 2019;83(8):1747–1754. doi: 10.1253/circj.CJ-19-0186
  41. Hsu JC, Huang YT, Lin LY. Stroke risk in hypertrophic cardiomyopathy patients with atrial fibrillation: a nationwide database study. Aging (Albany NY). 2020;12(23):24219–27. doi: 10.18632/aging.104133 EDN: YVPBCM
  42. Borre ED, Goode A, Raitz G, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost. 2018;118(12):2171–2187. doi: 10.1055/s-0038-1675400 EDN: TFLAOB
  43. Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38(9): 555–561. doi: 10.1002/clc.22435 EDN: XYQXPX
  44. Caldeira D, Costa J, Fernandes RM, et al. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2014;40(3):277–284. doi: 10.1007/s10840-014-9930-y EDN: BXQBUE
  45. Zeng J, Yu P, Cui W, et al. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: a PRISMA-compliant article. Medicine (Baltimore). 2020;99(25):e20782. doi: 10.1097/md.0000000000020782 EDN: KVDBXU
  46. Wang C, Yu Y, Zhu W, et al. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget. 2017;8(65):109703–109711. doi: 10.18632/oncotarget.19858 EDN: JOEFSP
  47. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol. 2011;90(10):1191–1200. doi: 10.1007/s00277-011-1267-3 EDN: XZADDB
  48. Hilkens NA, Algra A, Greving JP. Predicting major bleeding in ischemic stroke patients with atrial fibrillation. Stroke. 2017;48(11):3142–3144. doi: 10.1161/STROKEAHA.117.019183 EDN: TNNGOO
  49. Dalgaard F, Pieper K, Verheugt F, et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open. 2019;9(11):e033283. doi: 10.1136/bmjopen-2019-033283 EDN: PCWXHL
  50. Mori N, Sotomi Y, Hirata A, et al. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian Data from the DIRECT Registry). Am J Cardiol. 2019;124(7):1044–1048. doi: 10.1016/j.amjcard.2019.07.005 EDN: LRXXTL
  51. Yao X, Gersh BJ, Sangaralingham LR, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol. 2017;120(9):1549–1556. doi: 10.1016/j.amjcard.2017.07.051 EDN: GIQXWJ
  52. Nelson WW, Laliberté F, Patel AA, et al. Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Curr Med Res Opin. 2017;33(4): 631–638. doi: 10.1080/03007995.2016.1275936 EDN: FRRTRC
  53. Hijazi Z, Lindbäck J, Oldgren J, et al. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J. 2023;261:55–63. doi: 10.1016/j.ahj.2023.03.012 EDN: EKFHGC

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».